Coenzyme Q10 (Ubiquinone).

What does this test assess?

This method quantifies coenzyme Q10 (ubiquinone) from a dried blood spot. CoQ10 is an essential component of the mitochondrial electron transport chain and a potent endogenous antioxidant. Its measurement is important in evaluating mitochondrial function, statin-related myopathy risk, and supplementation efficacy.

Clinical indications include:

• Assessment of mitochondrial dysfunction in primary CoQ10 deficiency syndromes
• Monitoring of CoQ10 depletion during statin therapy (HMG-CoA reductase inhibitors share the mevalonate pathway with CoQ10 biosynthesis)
• Evaluation of myopathy, fatigue, and exercise intolerance potentially related to CoQ10 insufficiency
• Cardiovascular risk assessment — CoQ10 is concentrated in myocardial tissue
• Assessment in neurodegenerative conditions including Parkinson's disease and Huntington's disease
• Monitoring supplementation efficacy in clinical and wellness settings

About Coenzyme Q10

Coenzyme Q10 (also known as ubiquinone-10) is a lipid-soluble benzoquinone that is synthesised endogenously via the mevalonate pathway — the same biosynthetic route used for cholesterol production. It is present in virtually all human cells, with the highest concentrations found in organs with high metabolic demand: the heart, liver, kidneys, and skeletal muscle.

In the mitochondrial electron transport chain, CoQ10 shuttles electrons from complexes I and II to complex III, making it indispensable for oxidative phosphorylation and ATP generation. In its reduced form (ubiquinol), it also functions as a potent lipid-phase antioxidant, protecting cell membranes and circulating lipoproteins from peroxidation.

Primary CoQ10 deficiency is a group of autosomal recessive disorders caused by mutations in genes involved in ubiquinone biosynthesis. Clinical presentations range from severe infantile multisystem disease to isolated myopathy or cerebellar ataxia. Early diagnosis and supplementation can significantly improve outcomes in these conditions.

Secondary deficiency is far more common and is most frequently associated with statin therapy. Since statins inhibit HMG-CoA reductase — the rate-limiting enzyme in both cholesterol and CoQ10 biosynthesis — patients on long-term statin treatment may experience reduced CoQ10 levels, potentially contributing to statin-associated myopathy and fatigue. Monitoring CoQ10 in these patients can guide supplementation decisions.

Analytical technique

Coenzyme Q10 is extracted from a dried blood spot and quantified by isotope-dilution LC-MS/MS using a deuterium-labelled internal standard (CoQ10-d9). The method provides high sensitivity and specificity, accurately measuring total ubiquinone without interference from ubiquinol or other quinone species.

LC-MS/MS is the preferred analytical platform for CoQ10 due to its ability to resolve ubiquinone from structurally related compounds and achieve the low quantification limits required for clinical interpretation, particularly in deficiency states.

Literature

1. Littarru GP, Tiano L. “Bioenergetic and antioxidant properties of coenzyme Q10: recent developments.” Molecular Biotechnology, 2007, 37(1):31–37. 10.1007/s12033-007-0052-y
2. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. “Genetic bases and clinical manifestations of coenzyme Q10 deficiency.” Journal of Inherited Metabolic Disease, 2015, 38(1):145–156. 10.1007/s10545-014-9749-9
3. Banach M et al. “Statin therapy and plasma coenzyme Q10 concentrations — a systematic review and meta-analysis.” Pharmacological Research, 2015, 99:329–336. 10.1016/j.phrs.2015.07.012
4. Molyneux SL et al. “Coenzyme Q10: an independent predictor of mortality in chronic heart failure.” Journal of the American College of Cardiology, 2008, 52(18):1435–1441. 10.1016/j.jacc.2008.07.044
5. Crane FL. “Biochemical functions of coenzyme Q10.” Journal of the American College of Nutrition, 2001, 20(6):591–598. 10.1080/07315724.2001.10719063